Portuguese | English





Pressione Enter para iniciar a Busca.





Volume 112, Nº 4, April 2019

   

DOI: http://www.dx.doi.org/10.5935/abc.20190029

REVIEW ARTICLE

PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice

Filipe Ferrari

Ricardo Stein

Marcelo Trotte Motta

Emilio Hideyuki Moriguchi

Dr. Filipe Ferrari







Figure 1 – Mechanisms of PCSK9 involvement in LDL metabolism.





Keywords: Cardiovascular Diseases/physiopathology; Coronary Artery Disease/mortality; Proprotein Convertase 9; Cholesterol, LDL; Lipoproteins; Anticholesteromic Agents.